Waystar (WAY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
30 Apr, 2026Executive summary
Q1 2026 revenue reached $313.9 million, up 22% year-over-year, with net income of $43.3 million and adjusted EBITDA of $135.4 million, driven by strong subscription growth, AI innovation, and successful integration of Iodine.
Over 99% of revenue is recurring, with net revenue retention at 111% and client count with over $100,000 in trailing twelve-month revenue rising to 1,433, up 15% year-over-year.
AI-powered solutions now account for 40% of new bookings and nearly 40% of revenue, accelerating platform adoption and expanding the addressable market.
Integration of Iodine is ahead of plan, enhancing clinical and financial data convergence, cross-sell opportunities, and AI capabilities.
Launched new AI-powered recoupment solution and Prebill Anomaly Detection, delivering strong early ROI for providers.
Financial highlights
Q1 2026 revenue was $313.9 million, up 22% year-over-year; subscription revenue grew 38% to $172.2 million (55% of total), and volume-based revenue increased 7% to $139.5 million.
Adjusted EBITDA was $135.4 million, up 26% year-over-year, with a 43% margin, slightly above expectations due to favorable revenue mix.
Net income for Q1 2026 was $43.3 million, up 47.9% year-over-year, with a net income margin of 14%.
Unlevered free cash flow was $90.3 million, converting 67% of adjusted EBITDA.
Ended Q1 with $159 million in cash equivalents and $1.5 billion in gross debt; net debt stood at $1.32 billion.
Outlook and guidance
FY 2026 revenue guidance is $1.274–$1.294 billion (midpoint $1.284 billion, 17% year-over-year growth), with adjusted EBITDA of $530–$540 million and a margin expected to remain at 42–43%.
Non-GAAP net income projected at $317–$335 million and diluted non-GAAP EPS expected between $1.59 and $1.68.
Full-year guidance assumes normalized organic revenue growth of ~10% and less seasonality in patient payments.
Q2 sequential growth expected to be flat to 1%, with Q3 at 1–3%.
Sufficient liquidity is anticipated for at least the next 12 months, with ongoing investments in growth and technology.
Latest events from Waystar
- $1.25B AI-driven deal expands market by 15% and targets $15M+ in cost synergies.WAY
M&A Announcement9 Jul 2026 - AI-driven healthcare payments platform achieves strong growth and industry leadership.WAY
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - 2024 revenue up 19%, EBITDA margin 40.6%, net leverage 2.8x; 2025 targets 10% normalized growth.WAY
Q4 20248 Jul 2026 - Q2 revenue up 20% to $234.5M, with strong margins and $1B+ debt reduction post-IPO.WAY
Q2 20248 Jul 2026 - Q2 revenue rose 15% to $270.7M, guidance was raised, and a $1.25B acquisition was announced.WAY
Q2 20258 Jul 2026 - Q3 revenue up 22% to $240.1M, 40% EBITDA margin, $1B+ IPO, and raised full-year guidance.WAY
Q3 20248 Jul 2026 - AI-powered automation and data integration drive efficiency, growth, and industry leadership.WAY
46th Annual William Blair Growth Stock Conference2 Jun 2026 - All board proposals passed, including director elections and annual say-on-pay votes.WAY
AGM 20261 Jun 2026 - Record revenue, AI innovation, and strong governance mark a transformative year.WAY
Proxy filing17 Apr 2026